SCHEMBL31678128

SCHEMBL31678128

CCc1nc2n(CC(=O)Nc3ccc(F)cc3)c(C)c(Br)n2c(=O)c1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.45
▸ BACE1 P56817 1/20 0.45
▸ KDM4E B2RXH2 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MAPT P10636 3/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ HPGD P15428 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ MGAM O43451 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ SI P14410 1/20 0.40
▸ MGAM2 Q2M2H8 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ FPR1 P21462 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31677890 0.85 ACHE (0.41) ACHEBACE1KDM4ESMN1; SMN2MAPT
SCHEMBL31678008 0.84 KMT2A (0.45) ACHEBACE1KDM4ESMN1; SMN2MAPT
SCHEMBL31677686 0.81 RORC (0.39) ACHEBACE1KDM4ESMN1; SMN2MAPT
SCHEMBL31677834 0.79 KDM4E (0.38) ACHEBACE1KDM4ESMN1; SMN2MAPT
SCHEMBL31678102 0.79 KDM4E (0.40) KDM4EMAPTKMT2AMEN1ALDH1A1
SCHEMBL31677853 0.77 KDM4E (0.42) KDM4ESMN1; SMN2MAPTKMT2AMEN1
SCHEMBL31677892 0.77 KDM4E (0.43) KDM4EMAPTKMT2AMEN1LMNA
SCHEMBL31678064 0.77 KDM4E (0.38) KDM4EMAPTKMT2AMEN1ALDH1A1
SCHEMBL31678000 0.75 KMT2A (0.36) KDM4ESMN1; SMN2MAPTKMT2AMEN1
SCHEMBL31678822 0.72 KDM4E (0.44) KDM4ESMN1; SMN2MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS WRN, RECQL, BLM ACHE 4001/4885BACE1 4615/4885KDM4E 2390/4885
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS WRN, RECQL, BLM ACHE 3951/4885BACE1 4527/4885KDM4E 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback